{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Acrivon Therapeutics, Inc."},"Symbol":{"label":"Symbol","value":"ACRV"},"Address":{"label":"Address","value":"480 ARSENAL WAY SUITE 100, WATERTOWN, Massachusetts, 2472, United States"},"Phone":{"label":"Phone","value":"+1 617 207-8979"},"Industry":{"label":"Industry","value":" Medicinal Chemicals and Botanical Products "},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Company matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase."},"CompanyUrl":{"label":"Company Url","value":"www.acrivon.com"},"KeyExecutives":{"label":"Key Executives","value":[]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}